Navigation Links
Poniard Pharmaceuticals Announces Promising Data From Interim,Safety Analysis of Phase 1 Combination Trials of Picoplatin in,Colorectal and Prostate Cancers

se 2 Trials

Poniard anticipates initiating the Phase 2 components of the CRC and HRPC trials in the third quarter of 2007.

The Phase 2 CRC trial will include patients newly diagnosed with metastatic disease and will evaluate the safety and efficacy of picoplatin when combined with fluorouracil and leucovorin (FOLPI) and administered biweekly compared with oxaliplatin (Eloxatin(R)) at 85 mg/m2 combined with fluorouracil and leucovorin (FOLFOX). The objective of this multi-center, double-blind, randomized Phase 2 CRC trial of approximately 140 patients is to demonstrate that picoplatin is a neuropathy-sparing platinum that has an improved side effect profile compared to oxaliplatin, enabling a larger randomized Phase 3 CRC trial that has the potential to demonstrate superior safety and efficacy compared to FOLFOX.

The objective of the Phase 2 HRPC trial is to position picoplatin as the preferred platinum in combination with docetaxel plus prednisone and improve on the efficacy of docetaxel as a single agent plus prednisone. This multi- center, open-label, single-arm trial of approximately 30 patients is designed to demonstrate superior efficacy when picoplatin is administered with docetaxel plus prednisone every three weeks in the first-line setting.

About Picoplatin

Picoplatin, the Company's lead product candidate, is designed to overcome and prevent platinum resistance associated with chemotherapy in solid tumors. In addition to the ongoing Phase 1/2 clinical trials of intravenous picoplatin in CRC and HRPC, Poniard is evaluating intravenous picoplatin in an ongoing Phase 2 clinical trial in small cell lung cancer (SCLC). On May 1, 2007, the Company announced treatment of the first patient in its pivotal Phase 3 SPEAR (Study of Picoplatin Efficacy After Relapse) trial of intravenous picoplatin in SCLC, which is being conducted under a Special Protocol Assessment agreement with the U.S. Food and Drug Administration (FDA). Poniard re
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Poniard Pharmaceuticals Announces Clinical Data from Picoplatin Phase 2 Small Cell Lung Cancer Trial To Be Presented at American Society of Clinical Oncology Annual Meeting
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
6. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
7. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
8. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
Post Your Comments:
(Date:7/30/2015)... , July 30, 2015  Growth of the ... as they bring former prescription users to the OTC ... Kline forecasts robust Rx-to-OTC switch activity over the ... emerging along with many new brands entering the market ... over the next five years (even those with low ...
(Date:7/30/2015)... , July 30, 2015 ... new research report with market overview, trends, ... forecast, porter analysis, recent developments, competitive scenario ... Global Industry Insight: Biosensors Market Development and ... (Logo: http://photos.prnewswire.com/prnh/20150727/756778 ) Explore ...
(Date:7/30/2015)... July 30, 2015 Takeda Pharmaceutical Company ... to fulfill the post-marketing commitment and submissions of ... European Multi-Database Bladder Cancer Risk Characterization Study , ... study, conducted in four European countries, for pioglitazone ... to 10 years of follow-up. Findings demonstrate that ...
Breaking Medicine Technology:Rx-to-OTC Switches -- Game Changers for the U.S. OTC Drugs Market through 2019, Sees Kline 2Rx-to-OTC Switches -- Game Changers for the U.S. OTC Drugs Market through 2019, Sees Kline 3Global Biosensors Market (Size of $12,964 Million in 2014) to Witness 10% CAGR During 2015 - 2020 2Global Biosensors Market (Size of $12,964 Million in 2014) to Witness 10% CAGR During 2015 - 2020 3Global Biosensors Market (Size of $12,964 Million in 2014) to Witness 10% CAGR During 2015 - 2020 4Global Biosensors Market (Size of $12,964 Million in 2014) to Witness 10% CAGR During 2015 - 2020 5Takeda Announces Completion of the Pioglitazone Post-Marketing Commitment and Submission of Results to the EMA, the FDA and the PMDA 2Takeda Announces Completion of the Pioglitazone Post-Marketing Commitment and Submission of Results to the EMA, the FDA and the PMDA 3Takeda Announces Completion of the Pioglitazone Post-Marketing Commitment and Submission of Results to the EMA, the FDA and the PMDA 4Takeda Announces Completion of the Pioglitazone Post-Marketing Commitment and Submission of Results to the EMA, the FDA and the PMDA 5Takeda Announces Completion of the Pioglitazone Post-Marketing Commitment and Submission of Results to the EMA, the FDA and the PMDA 6
... BIEL), the maker of inexpensive, disposable drug-free topical pain ... of an article in the peer reviewed journal ... The article documents the clinical trial results of ... Plantar fasciitis, or heel pain, is a ...
... 19, 2012 According to Marcia Crosse (Director, Health Care ... to protect American health has been compromised. In her comments ... High-Risk List, she says : "The ... the health of all Americans. FDA,s role is far-reaching: from ...
Cached Medicine Technology:BioElectronics' Study on Plantar Fasciitis to be Published in The Journal of Foot and Ankle Surgery 2Physician-Patient Alliance for Health & Safety: Can There Be Too Much FDA Oversight? 2Physician-Patient Alliance for Health & Safety: Can There Be Too Much FDA Oversight? 3Physician-Patient Alliance for Health & Safety: Can There Be Too Much FDA Oversight? 4
(Date:7/31/2015)... ... July 31, 2015 , ... Girl Scouts of Historic Georgia and Peach State ... Girl Scout "Be a Friend First" program. Representatives from Peach State Health Plan presented ... State Health Plan and our parent company, Centene Corporation, are dedicated to raising anti-bullying ...
(Date:7/31/2015)... Seattle, WA (PRWEB) , ... July 31, 2015 , ... ... rapidly transforming the way we treat aging diseases. , BioViva announces it has ... to treat patients with Alzheimer’s Disease (AD) and find a cure. MaxLife will grant ...
(Date:7/31/2015)... ... , ... The Heart Fit Clinic has increased a patient's fitness level 60 ... 150 beats versus 100 beats, this is a big deal," says Diamond Fernandes, director ... to patients with heart disease," he adds. People with angina are able to do ...
(Date:7/31/2015)... York, NY (PRWEB) , ... July 31, 2015 , ... ... kidney disease, according to a study published today in Nature Communications and led by ... conducted in mice, suggests that variations in the gene RTN1 led to greater production ...
(Date:7/31/2015)... ... , ... Indosoft, Inc., is pleased to announce a major update to its ... contact center ACD system for Asterisk-based call centers . The new features make ... to the agent only when wanted, and allows for validation of data as the ...
Breaking Medicine News(10 mins):Health News:Peach State Health Plan Presents $10,000 Check for “Be a Friend First” Anti-Bullying Program to Local Girl Scouts 2Health News:BioViva USA, Inc.’s Alzheimer’s Disease Gene Therapy Human Trial 2Health News:BioViva USA, Inc.’s Alzheimer’s Disease Gene Therapy Human Trial 3Health News:Heart Fit Clinic Helps Patient Increase Fitness Level with External Counterpulsation 2Health News:Mount Sinai Researchers Find Key Gene Drives Kidney Disease Severity 2Health News:Mount Sinai Researchers Find Key Gene Drives Kidney Disease Severity 3Health News:Q-Suite 5.9 Adds Validation Tools to Call Center Software Agent Screen 2
... has issued a warning to leave no stone unturned to ... health department found, nearly 20%// of the children under 12 ... snacks on a daily basis. Healthy options like fruits ... ,The Health Minister, John Hill, said "We're working with ...
... New research has been released by Australian obesity experts that ... the international conference on obesity in Sydney there were three ... cent reduction in mortality rates in obese people who had ... around the upper part of the stomach for the procedure ...
... A team of surgeons at Children's National Medical Centre ... conjoined twins who shared a spinal cord and were// ... reported that Mateo and McHale Shaw from Sheboygan, Wisconsin ... 12 hours into Wednesday night. The hospital authorities had ...
... that men have a 4- to 5-point IQ advantage over ... on 100,000 17- to 18-year-//olds on the Scholastic Assessment Test ... is not obvious because girls mature faster than boys. This ... years. ,145 items from the SAT were examined ...
... is not rude but on the contrary would improve concentration.// ... Stirling in Scotland, led by Gwyneth Doherty-Sneddon have concluded in ... British Journal of Developmental Psychology, that looking away or gazing ... ,In the study that was conducted on a ...
... a week might reduce the risk of heart disease significantly.// ... Cardiology stated that as little as two servings of eight grams ... reduce the risk of heart disease by as much as 11%. ... the same kinds of nuts five days a week only results ...
Cached Medicine News:Health News:Successfully Separated Conjoined Twins In A Critical Yet Stable Condition 2Health News:Greater g factor in men responsible for sex differences in general mental ability 2Health News:Greater g factor in men responsible for sex differences in general mental ability 3
Indications For Usage: , Emergency use. , When medicant during ventilation is required. ...
... Indications For Usage: ... ,The monitoring lumen is ... of tracheal gases especially end-tidal ... pressure. , Introducing medication. ...
Indications For Usage: ,Laser surgery of the larynx or other areas in close proximity to the tracheal tube using CO2 or KTP laser beam....
Indications For Usage: ,Airway management during pediatric surgical procedures and intensive care....
Medicine Products: